Participating Companies

Axial Biotherapeutics, Inc.
The company's biotherapeutics products harness the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders, providing medical professionals and healthcare institutions with a new approach for diagnosing and treating PD and ASD and potentially other CNS diseases. [more information]

BerGenBio
[BGBIO:OS]
NKr3,076 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Bioarctic AB
[BIOA.B:ST]
SKr7,930 MM MCap
In the Parkinson’s Disease area, BioArctic has a partnership with Abbvie to develop ABBV-0805 and other anti-alpha synuclein antibodies. In addition, BioArctic is developing a blood brain barrier transport technology platform and imaging and biochemical biomarkers for Alzheimer’s and Parkinson’s diseases in various collaborations. [more information]

Boundless Bio
Developer of novel cancer therapeutics intended to understand and treat intraceable cancers. The company is in the process of developing a novel class of cancer drugs and extrachromosomal DNA (ecDNA) that eliminates cancer cells ability to employ ecDNA to survive, enabling healthcare professionals to treat most-difficult cancers. [more information]

Candesant Biomedical
Candesant Biomedical is developing a compelling product to unlock the potential of the sweat control market. Further, the product will provide a great value to the consumer with an economic incentive to the treating physicians. [more information]
Caribou Biosciences
Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited natural killer (NK) cell therapies, and engineered gut microbes. Investors include: Anterra Capital; Mission Bay Capital; Novartis [more information]

Cernostics, Inc.
Developer of tissue-based diagnostic test designed to quantify the complexity of the tissue system. The company's diagnostic test uniquely analyzes whole slide digital images with multiplexed fluorescence, providing physicians and patients with individualized, actionable information to improve outcomes and reduce the incidence and mortality of cancer. [more information]

CerSci Therapeutics
Developing a new generation of non-opioid medicines to treat acute post-operative and chronic neuropathic pain. Lead program in Phase 1 (MAD/SAD/Food Effect), CT-044, targeting reactive species that cause neuronal ion channel hyper-sensitization, known to trigger pain. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

Dynacure
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. [more information]

Exicure
[XCUR]
US$194 MM MCap
Cavrotolimod (AST-008) in Ph2 trials for patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, with Ph1b data presented at AACR 2020. XCUR-FXN in preclinical development for patients with Friedreich's Ataxia, using genetically targeted SNA therapies to remove FXN transcription blockage. [more information]

Faraday Pharmaceuticals
Chronic and acute agents to prevent cardiac and skeletal muscle loss by modulating neurohumoral pathways and restoring metabolic flexibility: lead candidate FDY-5301 Ph 3 ready for reperfusion injury following heart attack (AMI). $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage [more information]

Heidelberg Pharma AG
[HPHA:DB]
€179 MM MCap
Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. [more information]

HiFiBiO
The company's drug offers ultra-high-throughput antibody selection, unprecedented single-cell resolution and integrates deep-rooted biological expertise with comprehensive profiling technologies, enabling doctors to identify therapeutic molecules for the treatment of cancer and autoimmune disorders. [more information]

Incysus Therapeutics
The company's services focus on utilizing genetically modified gamma-delta T cells across a Drug Resistance Immunotherapy (DRI) platform that addresses the challenges faced while targeting cold, low mutation cancers, enabling the targeting of malignant cells and potentially more effective treatments for patients with difficult-to-treat solid tumor cancers. [more information]

Inventiva Pharma
[IVA:PA]
€525 MM MCap
The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Landos Biopharma
Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Lead asset BT-11 Phase 2 interim read out in mid-2020 in UC. [more information]

NervGen Pharma
[NGENF]
US$70 MM MCap
NervGen Pharma is a developing novel therapeutics for patients suffering from medical conditions related to nerve damage sustained as a result of (i) injury, such as in spinal cord injury, or (ii) neurodegenerative disease, such as MS or Alzheimer's disease. [more information]

PCI Biotech AS
[PCIB:OS]
NKr1,008 MM MCap
fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. The operating segment of the group is Research and development. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Secarna Pharmaceuticals GmbH
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and own in vitro screening assays. [more information]

Sensorion
[ALSEN:PA]
€125 MM MCap
Sensorion is a clinical-stage biotech and gene therapy company that specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. SENS-401 is in a Phase 2 clinical trial as a treatment for sudden sensorineural hearing loss. [more information]

Vaccinex, Inc.
[VCNX]
US$60 MM MCap
Its lead product, pepinemab, is an antibody against semaphorin 4D, a novel immunotherapy target to modulate immune response to solid tumors and chronic inflammation that drives neurodegenerative diseases. [more information]

Zentalis
[ZNTL]
US$1,610 MM MCap
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. [more information]